The drug manufacturer dossier provided indications and hints of an added benefit of simeprevir when the patients infected with hepatitis C virus (HCV) genotype 1 have been untreated before or have relapsed after initially successful treatment. It is not possible to rate the extent of added benefit, however…
“Hepatitis C (HCV) is the leading cause of liver cancer and accounts for more than 15,000 deaths in the U.S. each year,” said Jagpreet Chhatwal, Ph.D., assistant professor of Health Services Research at MD Anderson, and corresponding author on the study. “If we can improve access to treatment and incorporate more aggressive screening guidelines, we can reduce the number of chronic HCV cases, prevent more cases of liver cancer and reduce liver-related deaths,” Chhatwal said…
The findings, which appear in the November 29, 2013 issue of the journal Science, focus on a protein known as E2 envelope glycoprotein. "We’re excited by this development," said Ian A. …